We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

142 hedge funds and large institutions have $628M invested in Kiniksa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 57 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $7.55M | Put options by funds: $4.91M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

6% more funds holding

Funds holding: 134 → 142 (+8)

2.21% more ownership

Funds ownership: 98.97% → 101.18% (+2.2%)

4% more capital invested

Capital invested by funds: $606M → $628M (+$22.6M)

32% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 57

Holders
142
Holders Change
+8
Holders Change %
+5.97%
% of All Funds
2.07%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
29
Increased
39
Reduced
57
Closed
20
Calls
$7.55M
Puts
$4.91M
Net Calls
+$2.64M
Net Calls Change
+$2.03M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$27.9M
2
FFM
Fairmount Funds Management
Pennsylvania
+$6.72M
3
Walleye Capital
Walleye Capital
New York
+$5.38M
4
GIM
Granahan Investment Management
Massachusetts
+$3.09M
5
DCM
Driehaus Capital Management
Illinois
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$12.1M
2
State Street
State Street
Massachusetts
-$3.54M
3
Invesco
Invesco
Georgia
-$3.29M
4
Ameriprise
Ameriprise
Minnesota
-$2.98M
5
Millennium Management
Millennium Management
New York
-$2.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
101
American International Group
New York
$274K -$1.03K -63 -0.4%
Victory Capital Management
102
Victory Capital Management
Texas
$257K +$74.7K +4,547 +45%
Envestnet Asset Management
103
Envestnet Asset Management
Illinois
$254K -$291K -17,677 -55%
PCS
104
Personal CFO Solutions
New Jersey
$250K – – –
VOYA Investment Management
105
VOYA Investment Management
Georgia
$224K -$6.11K -372 -3%
Invesco
106
Invesco
Georgia
$222K -$3.29M -199,954 -94%
FRM
107
Fox Run Management
Connecticut
$220K +$206K +12,546 New
Manulife (Manufacturers Life Insurance)
108
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$219K -$7.1K -432 -3%
Janus Henderson Group
109
Janus Henderson Group
United Kingdom
$217K -$427 -26 -0.2%
YIH
110
Y-Intercept (HK)
Hong Kong
$214K +$200K +12,180 New
DTL
111
Dynamic Technology Lab
Singapore
$213K +$200K +12,160 New
Royal Bank of Canada
112
Royal Bank of Canada
Ontario, Canada
$203K +$74.5K +4,535 +64%
UBS AM
113
UBS AM
Illinois
$186K – – –
Wells Fargo
114
Wells Fargo
California
$186K -$384K -23,377 -69%
TRCT
115
Tower Research Capital (TRC)
New York
$181K +$148K +9,008 +702%
ACM
116
Aquatic Capital Management
Illinois
$151K +$141K +8,600 New
Zurich Cantonal Bank
117
Zurich Cantonal Bank
Switzerland
$121K -$1.97K -120 -2%
CUAMC
118
China Universal Asset Management Company
China
$71.9K +$52.4K +3,186 +350%
AIP
119
Ameritas Investment Partners
Nebraska
$54.3K – – –
AB
120
Amalgamated Bank
New York
$47K -$4.96K -302 -10%
SOW
121
State of Wyoming
Wyoming
$41.1K +$38.5K +2,342 New
Fidelity Investments
122
Fidelity Investments
Massachusetts
$40.1K +$1.46K +89 +4%
SPIA
123
Steward Partners Investment Advisory
New York
$39.5K – – –
MLICM
124
Metropolitan Life Insurance Company (MetLife)
New York
$32.4K – – –
EC
125
EntryPoint Capital
New York
$30.6K +$28.6K +1,743 New
3 4
5
6 7

KNSA Hedge Fund Activity: Q4 2023 in Review

142 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2023, worth a combined $628M — up 3.7% from $606M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KNSA positions and 20 closed out — a net gain of 9 holders — while 39 added to existing stakes and 57 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $27.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $12.1M sold.

  • 142 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2023, up from 134 in Q3 2023.
  • Funds reported $628M of Kiniksa Pharmaceuticals stock for Q4 2023, up 3.7% quarter-over-quarter.
  • 29 funds opened new Kiniksa Pharmaceuticals positions in Q4 2023 and 20 closed out, a net change of +9 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $27.9M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2023 was HHLR Advisors, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2023.